Vaxil’s primary platform enables integrated identification, isolation, and production OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES
Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products.
Vaxil is building a robust pipeline of immunotherapy products intended to target cancer antigens in an altogether novel and more specific manner.
| 1 | PLATFORM |  |
VAXIL’S PRIMARY PLATFORM: Proprietary Identification, isolation, and production OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES |
|||
| Pre Clinical | Phase I | Phase II | Phase III | |||
|---|---|---|---|---|---|---|
| 2 | ANTIGEN SPECIFIC IMMUNOTHERAPIES |  |
First VaxHit™ Generated Immunotherapy MUC1 selected as pilot target in order to demonstrate VaxHit’s ability as a platform to generate immunotherapies capable of targeting otherwise “untouchable” renowned antigens. | Phase-I/II complete15 myeloma patients Published BJH 2014 Orphan Drug | ||
| Additional SP specific immune therapies in progress | Follow-on products targeting other high profile cancer antigens | |||||
| 3 | SIGNAL PEPTIDE SPECIFIC ANTIBODIES |  |
Novel antibodies therapeutic & diagnostic | First ever SP-specific antibodies & far more specific against targets | ||
 |
Novel antibodies therapeutic & diagnostic | First ever SP-specific antibodies & far more specific against targets | ||||
| 4 | ANTI-INFECTIVES |  |
Derived from SP domains of 5 known TB vaccines | VaxHit™ has also led to vaccines for pathogens Superior immunity observed in large #’s | ||
VAXIL IMMUNOTHERAPY Intellectual Property rights
Vaxil believes its immunotherapy platform to be an altogether novel and advantageous avenue for targeting cancer. The Company has made efforts to protect its robust intellectual property portfolio in order to cover its proprietary products. Most importantly, however, is the protection afforded to VaxHit as a platform with the potential to generate additional immunotherapies targeting a range of cancer antigens in the same advantageous manner. Vaxil currently holds 6 fully issued patents, with an additional 10 patents pending.
Given Vaxil’s highly novel approach to immunotherapy, the Company believes its VaxHit™ platform possesses potential perhaps not yet understood or appreciated by the broader market. The Company is, therefore, utilizing the opportunity to amass a strong and broad intellectual property for ImMucin™ and even more so for VaxHit™ as an extensive platform with potential to generate additional immunotherapies targeting prevalent cancer antigens. Vaxil has already identified tens of possible immunotherapy product candidates utilizing its platform. Most importantly, VaxHit™ derived immunotherapy products (including ImMucin™) all contain the several critical advantages
Vaxil has five patent families, including 30 granted patents and eight patent applications with more work being done to expand the portfolio.
- The first patent family relates to the ImMucin™ product, a MUC1 signal peptide-based vaccine. This patent family includes patents in US, Europe, Australia, Canada, Israel and India, relating to the ImMucin™ vaccine and methods for using ImMucin™ such as for treating cancer and T-cell enrichment.
- The second patent family relates to immunogenic composition, specifically against a pathogen (e.g., tuberculosis, malaria, toxoplasma, EBV, HIV, herpes virus, and influenza). This patent family includes patents in US, Europe and South Africa.
- The third patent family relates to the antibodies produced by MUC1 signal peptides, and diagnostic and therapeutic methods using these antibodies. This patent family includes a US granted patent and patent applications in Europe, Australia, Canada, Israel and India.
- The fourth patents family relates to selective delivery of the drugs such as anticancer to endothelial cells using polymer-drug conjugates. This patent family includes granted patents in the US, Europe, and Israel
- The fifth patent family relates to COVID-19 immunogenic peptides, such as for use as vaccines. This patent family includes two US provisional applications.
USA
GRANTED
Patent Number
12,442,495
CANADA
GRANTED
Patent Number
2,665,816
EU
GRANTED
Patent Number
07827143.4
ISRAEL
GRANTED
Patent Number
197737
AUSTRALIA
GRANTED
Patent Number
2007298494
INDIA
PENDING
Patent Number
2595/DELNP/2009
ImMucin™ is the first immunotherapy to be derived from VaxHit platform, and has also been granted Orphan Drug Status from both the USA FDA and the EU EMA agencies, which provide certain additional incentives and market exclusivity.
USA
GRANTED
Patent Number
12,442,495
CANADA
GRANTED
Patent Number
2,665,816
EU
GRANTED
Patent Number
07827143.4
ISRAEL
GRANTED
Patent Number
197737
AUSTRALIA
GRANTED
Patent Number
2007298494
INDIA
PENDING
Patent Number
2595/DELNP/2009
Vaxil’s ImMucin™ immunotherapy was awarded Orphan Drug Status from the USA FDA and the European EMA agencies
ImMucin™ has completed a Phase I/II which included 15 myeloma cancer patients and validated VaxHit’s potential
as a platform for targeting renowned cancer antigens in an altogether unique and advantageous manner
Antibodies directed against signal peptides domains
USA
PENDING
Patent Number
14,344,837
CANADA
PENDING
Patent Number
2,848,819
ISRAEL
PENDING
Patent Number
231507
AUSTRALIA
PENDING
Patent Number
2012310086
INDIA
PENDING
Patent Number
2720/DELNP/2014
Antigen specific multiple epitope anti-infective
USA
GRANTED
Patent Number
13,384,286
EU
PENDING
Patent Number
10747083.3
INDIA
PENDING
Patent Number
1224/CHENP/2012
South Africa
GRANTED
Patent Number
2012/01137